厄贝沙坦对维持性血液透析患者氧化应激的影响

目的观察厄贝沙坦对维持性血液透析(MHD)患者氧化应激的影响。方法65例MHD患者随机分为厄贝沙坦治疗组和对照组。治疗组常规降血压基础上口服厄贝沙坦150~300mg/d降血压;对照组常规降血压治疗。治疗组与对照组于试验前及试验2个月后血液透析前采集空腹外周静脉血5ml分别检测血浆MDA、SOD。结果治疗组治疗前后比较,MDA水平下降,SOD水平升高(P<0.05)。治疗组服用厄贝沙坦2个月后与对照组比较,MDA水平下降,SOD水平升高(P<0.05或P<0.01)。结论厄贝沙坦能改善MHD患者抗氧化能力,降低MHD患者的氧化应激水平。

Influence of Irbesartan on Oxidative Stress in Maintenance Hemodialysis Patients

Objective To explore the influence of irbesartan on oxidative stress in maintenance hemodialysis （MHD） patients. Method A total of 65 cases of MHD patients were randomly divided into 2 groups：treat- ment group and control group. Besides the ordinary treatment to decrease blood pressure, the patients of treat- ment group were given irbesartan 150 -300mg per day for two months. Fasting peripheral blood was collected before hemodialysis in both groups. Serum levels of oxidative product malondialdehyde（MDA） and anti-oxidative product superoxide dismutase （SOD） were measured before and after the experiment. Results In treat- ment group serum MDA decreased and serum SOD increased after treatment comparing with those before treat- ment（P 〈 0.05）. Serum MDA decreased and serum SOD increased after treatment comparing with those in control group （P 〈 0.05 or P 〈 0.01 ）. Conclusions Irbesartan can improve anti-oxidative level and decrease the level of oxidative stress in MHD patients.